Verify MTM eligibility, wellness-visit and care-plan coverage, and GUIDE participation before changing dementia drugs. Deprescribing means carefully reducing or stopping drugs that may harm more than help. Costs and coverage depend on the specific plan, clinic and drugs. Use the checks below to prepare questions and avoid surprise bills.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which Medicare reviews cover medication checks?
- What does GUIDE pay for?
- Which drugs need a closer look?
- Can reviews lower spending?
- What to verify before the visit?
Which Medicare reviews cover medication checks?
Medicare.gov says Part D plans must offer Medication Therapy Management reviews at no extra cost to qualifying members. Qualifying members have multiple chronic conditions, multiple drugs and high drug costs. Alzheimer's and dementia count as a qualifying condition. See Medicare safety-management guidance for program rules. Medicare.gov says Part B covers an Annual Wellness Visit once every 12 months.
The visit must include prescription review and cognitive screening. It costs $0 when the provider accepts assignment. Details are in Medicare yearly wellness visits. The Alzheimer's Association says clinicians can bill CPT 99483 for a longer cognitive assessment. The visit must include medication reconciliation and review for high-risk drugs. It must also produce a written care plan.
What does GUIDE pay for?
The CMS Innovation Center launched the 8-year GUIDE dementia model on July 1, 2024. It began with 390 participating organizations. GUIDE pays for care coordination, caregiver education and medication management.
It also funds respite care up to $2,500 per patient per year. Availability varies by clinic and region. Confirm GUIDE participation with the specific clinic and plan.
Which drugs need a closer look?
The American Geriatrics Society 2023 Beers Criteria advise extra caution in adults 65 and older. They advise avoiding benzodiazepines, highly anticholinergic drugs and routine antipsychotics. Risks include falls, delirium, cognitive decline and hospitalization.
FDA labeling carries a boxed warning for all antipsychotics used for dementia-related psychosis. Elderly patients had about 1.6 to 1.7 times higher death risk in 10-week trials. The drugs are not approved for that use. See FDA approved labeling.
Can reviews lower spending?
A University at Buffalo study in the Journal of the American Geriatrics Society found about 34% of older adults received a potentially inappropriate drug. Those patients paid on average over $450 extra per year. They also faced more hospitalizations.
Read the University study report. Deprescribing reviews can reduce spending by stopping low-value drugs. Savings vary by drug, dose and coverage. Ask the pharmacist which stops save money without harming care.
What to verify before the visit?
Medicare.gov and CMS say checks work best with complete drug information. Confirm these points with the specific plan and clinic: Never stop sedatives abruptly on your own. Taper sedatives only under clinician supervision because abrupt stopping can cause harm.
- Confirm MTM eligibility and how to book the pharmacist review.
- Confirm GUIDE participation and what caregiver support it covers.
- Bring every prescription, over-the-counter drug, vitamin and supplement to the wellness or 99483 visit.
- Ask which drugs are high-risk, what safer options exist, and what follow-up is planned.
